Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 7.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,598,722 shares of the specialty pharmaceutical company's stock after selling 129,900 shares during the quarter. Renaissance Technologies LLC owned about 2.90% of Supernus Pharmaceuticals worth $57,810,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its stake in Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after buying an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC purchased a new position in shares of Supernus Pharmaceuticals in the 4th quarter valued at approximately $52,000. Headlands Technologies LLC increased its stake in shares of Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 1,015 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in Supernus Pharmaceuticals during the 4th quarter valued at about $72,000. Finally, Venturi Wealth Management LLC purchased a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth $92,000.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the business's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now owns 10,149 shares in the company, valued at $402,915.30. The trade was a 48.29 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,104 shares of company stock worth $440,263. Corporate insiders own 9.30% of the company's stock.

Remove Ads

Supernus Pharmaceuticals Stock Down 0.7 %

SUPN stock traded down $0.22 during mid-day trading on Tuesday, hitting $31.38. 76,486 shares of the company were exchanged, compared to its average volume of 491,063. The business has a fifty day simple moving average of $33.37 and a 200-day simple moving average of $35.07. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The firm has a market capitalization of $1.75 billion, a P/E ratio of 29.33 and a beta of 0.90.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Cantor Fitzgerald reissued a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com lowered Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, April 9th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.